McKesson (NYSE:MCK) Stock Gets Price Target Bump from Leerink Partners

McKesson (NYSE:MCK) had its price target hoisted by equities researchers at Leerink Partners from $1,070.00 to $1,200.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective would indicate a potential upside of 10.80% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley set a $977.00 price target on shares of McKesson in a research report on Tuesday, October 6th. Wells Fargo & Company upped their price objective on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Citigroup increased their price objective on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Barclays lifted their target price on McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. Finally, TD Cowen boosted their target price on McKesson from $989.00 to $1,006.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, McKesson currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.82.

McKesson Price Performance

Shares of MCK stock traded up $13.57 during trading on Thursday, hitting $1,083.01. 822,047 shares of the stock traded hands, compared to its average volume of 917,825. The firm has a market capitalization of $126.27 billion, a P/E ratio of 28.98, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27. The firm’s fifty day moving average price is $931.17 and its 200-day moving average price is $865.74. McKesson has a 52-week low of $723.68 and a 52-week high of $1,121.50.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The business had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the business earned $9.86 earnings per share. As a group, equities research analysts expect that McKesson will post 44.71 earnings per share for the current year.

Insiders Place Their Bets

In other McKesson news, EVP Francisco Fraga sold 800 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $995.80, for a total value of $796,640.00. Following the transaction, the executive vice president directly owned 5,423 shares of the company’s stock, valued at approximately $5,400,223.40. The trade was a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley Lerman sold 301 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,212 shares of company stock valued at $1,164,182. 0.06% of the stock is owned by company insiders.

Institutional Trading of McKesson

Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in McKesson in the 2nd quarter worth approximately $8,156,743,000. Bank of America Corp DE lifted its stake in shares of McKesson by 2.4% during the 1st quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock worth $1,331,552,000 after purchasing an additional 35,916 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of McKesson by 3.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 922,573 shares of the company’s stock worth $697,096,000 after purchasing an additional 29,747 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of McKesson during the second quarter worth $656,566,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of McKesson during the second quarter worth $651,462,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted EPS of $11.68, ahead of analysts’ roughly $10.70–$10.72 estimates, while revenue of $110.96 billion topped expectations of $109.9 billion and grew about 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: The company raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40. Management cited specialty distribution, higher prescription volumes and GLP-1 momentum as growth drivers. McKesson Corp (MCK) Q2 2027 Earnings Call Highlights
• Positive Sentiment: TD Cowen and Evercore ISI each raised their price target to $1,200, from $1,006 and $1,000, respectively—signaling improved analyst expectations after the results. TD Cowen Adjusts Price Target Evercore ISI Adjusts Price Target
• Neutral Sentiment: McKesson closed its $2.25 billion Precision Medicine Group acquisition, expanding its position in precision medicine. The deal offers growth potential, with execution and integration still to come. McKesson Outlook and Precision Medicine Deal
• Negative Sentiment: Some investors appeared cautious despite the earnings beat, with reports describing an after-hours stock dip. Earlier coverage also flagged branded-drug pricing pressure as a potential headwind. Q2 Earnings and Outlook

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.